DK1136081T3 - Sammensætninger med forhalet frigivelse til parenteral indgivelse af makrolider - Google Patents

Sammensætninger med forhalet frigivelse til parenteral indgivelse af makrolider

Info

Publication number
DK1136081T3
DK1136081T3 DK01302438T DK01302438T DK1136081T3 DK 1136081 T3 DK1136081 T3 DK 1136081T3 DK 01302438 T DK01302438 T DK 01302438T DK 01302438 T DK01302438 T DK 01302438T DK 1136081 T3 DK1136081 T3 DK 1136081T3
Authority
DK
Denmark
Prior art keywords
macrolides
delayed
parenteral administration
release compositions
compositions
Prior art date
Application number
DK01302438T
Other languages
English (en)
Inventor
William David Steber
Sivaja Ranjan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1136081T3 publication Critical patent/DK1136081T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK01302438T 2000-03-20 2001-03-16 Sammensætninger med forhalet frigivelse til parenteral indgivelse af makrolider DK1136081T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19069900P 2000-03-20 2000-03-20

Publications (1)

Publication Number Publication Date
DK1136081T3 true DK1136081T3 (da) 2005-02-21

Family

ID=22702398

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01302438T DK1136081T3 (da) 2000-03-20 2001-03-16 Sammensætninger med forhalet frigivelse til parenteral indgivelse af makrolider

Country Status (15)

Country Link
US (1) US6552002B2 (da)
EP (1) EP1136081B1 (da)
JP (1) JP4817515B2 (da)
AR (1) AR027681A1 (da)
AT (1) ATE286406T1 (da)
AU (1) AU781682B2 (da)
BR (1) BR0101090A (da)
CA (1) CA2341281C (da)
DE (1) DE60108189T2 (da)
DK (1) DK1136081T3 (da)
ES (1) ES2233566T3 (da)
MX (1) MXPA01002861A (da)
NZ (1) NZ510538A (da)
PT (1) PT1136081E (da)
SI (1) SI1136081T1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2561108T3 (es) * 2001-10-19 2016-02-24 Idexx Laboratories, Inc. Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo
UY27412A1 (es) * 2002-08-12 2003-06-30 Carlson Internat Inc Un nuevo producto para el combate de garrapatas y el proceso para la prepaacinn.
US7906128B2 (en) * 2002-10-21 2011-03-15 Wyeth Llc Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
US7396819B2 (en) * 2003-08-08 2008-07-08 Virbac Corporation Anthelmintic formulations
WO2005094210A2 (en) * 2004-03-12 2005-10-13 The Hartz Mountain Corporation Multi-action anthelmintic formulations
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
CN102143920B (zh) 2008-09-09 2015-05-13 旭硝子株式会社 玻璃板的风冷强化装置及风冷强化方法
UY33282A (es) * 2010-03-25 2011-09-30 Novartis Ag Composiciones endoparasiticidas
KR101494594B1 (ko) * 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
JP6273252B2 (ja) 2012-03-13 2018-01-31 バイエル・ニュージーランド・リミテッド 長時間作用型の組成物
JP5717034B2 (ja) * 2012-08-27 2015-05-13 丸和バイオケミカル株式会社 マクロライド系化合物を含有する土壌線虫防除用薬剤
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
JP6363115B2 (ja) * 2013-02-28 2018-07-25 ミラ ファーマ コーポレイション 注射可能局所麻酔半固体製剤およびその組成物
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
ITUB20153652A1 (it) 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
GB2552952B (en) * 2016-08-12 2020-03-04 Norbrook Lab Ltd Moxidectin topical liquid formulations
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
WO2020242862A1 (en) * 2019-05-24 2020-12-03 Piedmont Animal Health Inc. Long-acting injectable formulations and use thereof
CN116744917A (zh) 2020-09-04 2023-09-12 礼蓝美国公司 适口调配物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389397A (en) * 1980-08-04 1983-06-21 Merck & Co., Inc. Solubilization of ivermectin in water
JPS57171919A (en) * 1981-04-17 1982-10-22 Nippon Kayaku Co Ltd Orally administering composition for veterinary purposes
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
CA2233016C (en) 1995-09-25 2007-07-17 Ashmont Holdings Limited Anthelmintic macrocyclic lactone compositions
DE19613972A1 (de) * 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
WO1997046204A2 (en) * 1996-06-05 1997-12-11 Ashmont Holdings Limited Injectable compositions
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
CA2211949A1 (en) * 1997-07-21 1999-01-29 David Farley Johnson Nonaqueous compositions for parenteral administration

Also Published As

Publication number Publication date
CA2341281C (en) 2010-11-02
DE60108189T2 (de) 2005-06-02
CA2341281A1 (en) 2001-09-20
AU781682B2 (en) 2005-06-09
NZ510538A (en) 2002-06-28
DE60108189D1 (de) 2005-02-10
MXPA01002861A (es) 2002-06-04
US20020004486A1 (en) 2002-01-10
JP2001261558A (ja) 2001-09-26
PT1136081E (pt) 2005-03-31
EP1136081B1 (en) 2005-01-05
ES2233566T3 (es) 2005-06-16
ATE286406T1 (de) 2005-01-15
AU2641501A (en) 2001-09-27
JP4817515B2 (ja) 2011-11-16
AR027681A1 (es) 2003-04-09
SI1136081T1 (en) 2005-04-30
US6552002B2 (en) 2003-04-22
BR0101090A (pt) 2001-11-06
EP1136081A1 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
DK1136081T3 (da) Sammensætninger med forhalet frigivelse til parenteral indgivelse af makrolider
DK1421939T3 (da) Præparat med opretholdt frigivelse af en makrolidforbindelse såsom tacrolimus
DK1296656T3 (da) Fremgangsmåde til fremstilling af et præparat
DK2158905T3 (da) Sammensætning til transdermal administration af fentanyl
DK1326585T4 (da) Fremgangsmåde til fremstilling af pulverformuleringer
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1309327T3 (da) Farmaceutiske sammensætninger af østrogene midler
DK1277722T3 (da) Fremgangsmåde til fremstilling af methanol
DK1341531T3 (da) Lactamforbindelser til inhibering af beta-amyloidpeptidfrigivelse eller - syntese
DK1253153T3 (da) Fremgangsmåde til fremstilling af 4"-substituerede-9-deoxo-9a-aza-9a-homoerythromycin-A-derivater
DK1044969T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af anti-cancer forbindelser
DK1303490T3 (da) N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater
IS6508A (is) Lyfjasamsetningar af glycogen fosfórýlasa lötum
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
DK1349580T3 (da) Fremgangsmåde til forbedring af stabiliteten af en farmaceutisk sammensætning
DK1147075T3 (da) Fremgangsmåde til fremstilling af L-phenylephrinhydrochlorid
DK1407037T3 (da) Fremgangsmåde til fremstilling af tagatose
DK1272489T3 (da) Fremgangsmåde til præparation af cabergolins krystallinske form I
IS2349B (is) Lyfjafræðileg drónedarón samsetning til gjafar utan meltingarvegar
DK1345939T3 (da) Fremgangsmåde til fremstilling af sulfonamidsubstituerede imidazotriazinoner
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK1158963T3 (da) Sammensætninger af betahistin med kontrolleret frigivelse
DK1292586T3 (da) Fremgangsmåde til fremstilling af pyrazolopyrimidinoner
DK1591122T3 (da) Fremgangsmåde til indgivelse af bisphosphonater